REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
8.76
-0.03 (-0.34%)
Nov 4, 2024, 4:00 PM EST - Market closed
REGENXBIO Employees
REGENXBIO had 344 employees as of December 31, 2023. The number of employees decreased by 57 or -14.21% compared to the previous year.
Employees
344
Change (1Y)
-57
Growth (1Y)
-14.21%
Revenue / Employee
$258,849
Profits / Employee
-$700,802
Market Cap
432.95M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Ginkgo Bioworks Holdings | 1,218 |
National Research | 435 |
MeiraGTx Holdings | 425 |
Lexicon Pharmaceuticals | 285 |
Butterfly Network | 225 |
Absci | 155 |
Zevra Therapeutics | 69 |
Mind Medicine (MindMed) | 57 |
RGNX News
- 1 day ago - REGENXBIO to Participate in Upcoming Investor Conferences - PRNewsWire
- 4 days ago - REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track - Seeking Alpha
- 6 days ago - REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights - PRNewsWire
- 15 days ago - REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024 - PRNewsWire
- 18 days ago - REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting - PRNewsWire
- 6 weeks ago - REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference - PRNewsWire
- 7 weeks ago - REGENXBIO Appoints Mitchell Chan as Chief Financial Officer - PRNewsWire
- 2 months ago - REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect - PRNewsWire